GlucoTrack
GCTK
1 hedge funds and large institutions have $96K invested in GlucoTrack in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
40% less capital invested
Capital invested by funds: $161K → $96K (-$65K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boston Financial Management
Boston,
Massachusetts
| $96K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$48K | -2 | Closed |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$3K | – | – |
|
GCTK Hedge Fund Activity: Q1 2022 in Review
1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q1 2022, worth a combined $96K — down 40% from $161K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GCTK and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $48K sold.
- 1 institutional investor held GlucoTrack (GCTK) as of Q1 2022, down from 2 in Q4 2021.
- Funds reported $96K of GlucoTrack stock for Q1 2022, down 40% quarter-over-quarter.
- 0 funds opened new GlucoTrack positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest GlucoTrack seller in Q1 2022 was Susquehanna International Group, an estimated $48K sold.
Based on aggregated 13F filings for Q1 2022.